Skip to main content

Table 1 Percentages of patients with injection site-related adverse events

From: A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

Preferred term

Patients with 1 or more event (N = 1752) n (%)

Patients with events occurring more than once n (%)

Any injection site-related AE

92 (5.3)

19 (20.7)

Injection site pain

50 (2.9)

6 (12.0)

Injection site reaction

10 (0.6)

1 (10.0)

Injection site mass

8 (0.5)

3 (37.5)

Injection site swelling

8 (0.5)

3 (37.5)

Injection site induration

6 (0.3)

1 (16.7)

Injection site nodule

6 (0.3)

2 (33.3)

Injection site irritation

5 (0.3)

2 (40.0)

Injection site abscess

4 (0.2)

 

Injection site haemorrhage

4 (0.2)

1 (25.0)

Injection site warmth

3 (0.2)

 

Injection site erythema

2 (0.1)

 

Injection site discolouration

1 (0.1)

 

Injection site extravasation

1 (0.1)

 

Injection site oedema

1 (0.1)

 

Injection site paraesthesia

1 (0.1)

 

Injection site rash

1 (0.1)

1 (100.0)

  1. Abbreviation: AE adverse event.